Kyntra Bio Posts Quarterly Profit Flip on Negative Revenue While Half-Year Loss Widens

Bottom line

For the three-month reporting period identified under 10-Q period-ended-2026-06-30 (accession 0001193125-26-349183, CIK 0000921299, ticker KYNB, company KYNTRA BIO, INC.), the headline numbers flip from a loss to a profit on the bottom line, but the top line and the operating layer both deteriorate. Earnings Per Share, Diluted moves from a loss of -$1.88 per diluted share USD/SHARES in the three months ended June 30, 2025 to a profit of $2.96 per diluted share USD/SHARES in the three months ended June 30, 2026, and Net Income (Loss) Attributable to Parent turns from a loss of -$7,603,000 USD to a profit of $11,974,000 USD — a clean loss-to-profit transition on the quarter. Operating Income (Loss), by contrast, stays negative on the quarter: it was -$12,052,000 USD a year ago and is -$17,574,000 USD now, a deeper quarterly operating loss. Revenue from Contract with Customer, Excluding Assessed Tax was $1,348,000 USD a year earlier and is -$1,474,000 USD in the current quarter — a swing from positive revenue to effectively no revenue on the quarter.

On the six-month year-to-date window (the six months ended June 30, 2026 vs. the six months ended June 30, 2025), the picture is uniformly negative and never returns to profit. Revenue from Contract with Customer, Excluding Assessed Tax moves from $4,088,000 USD to $2,264,000 USD, a clear decline. Operating Income (Loss) remains a loss both periods, going from -$26,972,000 USD to -$31,392,000 USD, a wider loss. Net Income (Loss) Attributable to Parent stays a loss, shifting from -$2,964,000 USD to -$3,224,000 USD, and Earnings Per Share, Diluted stays negative at -$0.8 per diluted share USD/SHARES versus -$1.88 per diluted share-comparable reporting. The filing evidence does not attribute this change to any single cause.

Filing scope covers the unaudited condensed consolidated financial statements of the single reportable segment (development and commercialization of novel therapeutics), with continuing-operations treatment of FibroGen International following the AstraZeneca sale, and reference to collaboration-revenue accounting under Note 4, equity transactions under Note 10, discontinued-operations treatment under Note 3, and treasury share movement under Note 2. Clinical milestones referenced in the narrative include the Phase 3 roxadustat MDS trial and the Phase 2 FG-(omitted) mCRPC program, with Item 1 through Item 6 and Item 1A covering legal, risk, equity-sale, controls, and exhibits sections. The filing evidence contains no peer or industry comparison.

For readers comparing windows, the quarter shows a profitability flip masking a revenue and operating-income deterioration, while the half-year shows a loss that widens on operating income and revenue, consistent with a period in which the China roxadustat contribution has been reclassified out of continuing operations. Readers wanting a contrast where both windows posted profit on higher revenue can cross-check the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows.

Financial performance

- Reported facts: For the three-month period, Revenue from Contract with Customer, Excluding Assessed Tax was -$1,474,000 USD, compared with $1,348,000 USD in the prior-year three-month window, per the unaudited condensed consolidated statements of operations. For the six-month year-to-date window, the same revenue line was $2,264,000 USD versus $4,088,000 USD. Operating Income (Loss) for the three-month period was -$17,574,000 USD against -$12,052,000 USD in the prior year, and the six-month operating result was -$31,392,000 USD versus -$26,972,000 USD.

Net Income (Loss) Attributable to Parent for the three-month period was $11,974,000 USD, against -$7,603,000 USD in the prior-year quarter, and the six-month net result was -$3,224,000 USD versus -$2,964,000 USD. 8 per diluted share USD/SHARES for the six-month window. - Management explanations: Management frames the period around the late-stage roxadustat program, describing continuing preparation for the Phase 3 trial in lower-risk MDS, the prior FDA Orphan Drug Designation, and ongoing evaluation of internal development versus partnership paths.

S. GAAP, on a going-concern basis, with management asserting that existing cash and cash equivalents are sufficient to fund planned operating requirements for at least the cited number of months following issuance. Discontinued-operations treatment follows the AstraZeneca share purchase transaction captured in Note 3, and the company reports as a single operating segment.

- Analyst inference: The authorized year-over-year comparisons show revenue moving in opposite directions on the two windows — declining on the three-month view and declining on the six-month view — while net income transitions from a loss to a profit on the three-month comparison and remains a loss on the six-month comparison. Operating income is a loss on both windows and deteriorates year over year on each, which is consistent with a development-stage cost base outpacing a smaller reported top line. The diluted EPS swing on the quarter mirrors the net-income transition from loss to profit; the half-year EPS remains negative.

- Counter-evidence: The reported half-year operating loss is wider than the prior-year half-year loss, even as the three-month net result flipped to a profit, so any read-through from the quarter swing to a clean profitability inflection would be premature. The collaboration, license and revenue line tied to Note 4 and the equity activity disclosed in Note 10 provide the only labeled contextual anchors, and neither is quantified in the prose here. The filing evidence does not attribute this change to any single cause.

- Unknowns: No peer or industry benchmark is available in the filing evidence, and no forward quantitative guidance is reproduced. The filing evidence contains no peer or industry comparison.

Operating drivers and segments

- The company reports as a single operating segment focused on development and commercialization of novel therapeutics for serious unmet medical needs, so segment-level revenue or margin breakdowns are not separately presented in the cited disclosure. - Revenue from Contract with Customer, Excluding Assessed Tax was -$1,474,000 USD for the three months ended June 30, 2026, direction negative, versus $1,348,000 USD for the three months ended June 30, 2025, direction positive; the authorized comparison records a decrease and the current period is negative rather than positive, a swing into a contra-revenue position rather than a straightforward decline. - Revenue from Contract with Customer, Excluding Assessed Tax was $2,264,000 USD for the six months ended June 30, 2026, direction positive, versus $4,088,000 USD for the six months ended June 30, 2025, direction positive; the authorized comparison records a decrease, so the year-to-date top line softened even while remaining positive. - Operating Income (Loss) was -$17,574,000 USD for the three months ended June 30, 2026, direction negative, versus -$12,052,000 USD for the three months ended June 30, 2025, direction negative; the authorized comparison records a decrease, meaning the quarterly operating loss deepened year over year. - Operating Income (Loss) was -$31,392,000 USD for the six months ended June 30, 2026, direction negative, versus -$26,972,000 USD for the six months ended June 30, 2025, direction negative; the authorized comparison records a decrease, so the year-to-date operating loss also widened.

- Management describes a strategic shift in January of the current year, rebranding from FibroGen, Inc. to Kyntra Bio, Inc., with the common stock trading on Nasdaq under the new symbol referenced through KYNB, and pivoting the portfolio toward oncology and rare disease assets rather than the historical anemia franchise. - Management closed the sale of its China operations through FibroGen International (Hong Kong) Ltd. in August of the current year, transferring all China roxadustat assets and FibroGen Beijing to AstraZeneca Treasury Limited, and deconsolidated the subsidiary; this Transaction is the basis for the Discontinued Operations disclosure tied to the cited note on the divestiture. - Management continues to advance FG-, a potential first-in-class antibody-drug conjugate targeting an oncology pathway for metastatic castration-resistant prostate cancer, paired with an associated PET biomarker, alongside development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes, where the third-phase trial protocol has been finalized per the cited phase reference and preparations are ongoing while partnership options are evaluated. - Management cites Food and Drug Administration Orphan Drug Designation granted for roxadustat in MDS in December of the prior year as validation of the program, and flags two recently issued Accounting Standards Updates on expense disaggregation disclosures that the Company has not yet adopted.

Cash flow and capital

Reported facts: - Operating cash flow for the six months ended June 30, 2026 was a use of cash, compared with a source of cash in the six months ended June 30, 2025. The year-over-year authorized direction is a decrease, and the half-year cash flow moved from providing cash to consuming cash. - Investing cash flow for the six months ended June 30, 2026 was a source of cash, versus a use of cash in the six months ended June 30, 2025. The year-over-year authorized direction is an increase, and investing activities shifted from consuming cash to providing cash. - Financing cash flow for the six months ended June 30, 2026 was a use of cash, as it also was in the six months ended June 30, 2025. The year-over-year authorized direction is an increase, meaning the financing outflow was smaller in absolute terms than the prior-year outflow. - Capital expenditures, captured as payments to acquire property, plant, and equipment, were reported at zero in the six months ended June 30, 2026 versus a positive outflow in the six months ended June 30, 2025. The year-over-year authorized direction is a decrease, consistent with a step-down in ongoing property, plant, and equipment investment. - The balance sheet at the balance sheet date of June 30, 2026 shows cash and cash equivalents of $50,644,000, accounts receivable of $347,000, and accounts payable of $7,510,000.

Management explanations: - The narrative points to FibroGen Europe's voluntary bankruptcy filing in April (year omitted) and the subsequent April (year omitted) Helsinki District Court bankruptcy declaration, which triggered deconsolidation. FibroGen Europe held the TEKES Loans, which were non-recourse to KYNTRA BIO, INC.. Upon deconsolidation, KYNTRA BIO, INC. recognized a gain on deconsolidation and measured any retained equity interest in the subsidiary at a fair value of zero as of April (year omitted). - Management also describes the February (year omitted) Share Purchase Agreement with AstraZeneca Treasury Limited covering the sale of FibroGen International, which is addressed in Note 3.

Analyst inference: - The combination of an operating cash outflow, an investing cash inflow, and a smaller financing cash outflow suggests KYNTRA BIO, INC. is funding the period's operating deficit in part by drawing on investment maturities or sales rather than by raising new external financing, while continuing to repay or net-settle financing obligations. - The step-down in property, plant, and equipment payments to zero, on top of an already smaller financing outflow, indicates a tighter capital allocation stance heading into the second half of the fiscal year, even as cash and equivalents remain on hand. - The investing inflow against an operating outflow, with no incremental capital spending, is consistent with a posture of preserving liquidity while clinical and licensing commitments continue to absorb cash.

Counter-evidence: - The filing does not break out how much of the investing inflow reflects maturities of marketable securities versus proceeds from the FibroGen International divestiture under Note 3; the two are reported together as net investing cash flow. - The deconsolidation gain on FibroGen Europe is presented in the income statement, but the cash impact, if any, is not separately disclosed in the cash flow categories used here.

Unknowns: - The driver of the swing in operating cash flow from a source to a use is not stated in the cited material. The filing evidence does not attribute this change to any single cause. - The composition of working-capital movements behind accounts payable and accounts receivable at the balance sheet date of June 30, 2026 is not separately explained in the evidence available to this section. The filing evidence does not attribute this change to any single cause. - Any segment-level cash flow split between continuing and discontinued operations is not provided here. The filing evidence contains no peer or industry comparison.

Peer and historical context

Looking at KYNTRA BIO, INC.'s interim results on the same basis as its own prior-year periods, the year-to-date window covers the six months ended June 30, 2025 versus the six months ended June 30, 2026, and the three-month window covers the three months ended June 30, 2025 versus the three months ended June 30, 2026. The ledger does not include any peer company, sector index, or industry benchmark figures, so the comparison below is limited to the company's own historical windows inside this 10-Q filing under accession 0001193125-26-349183 for period-ended-2026-06-30.

Revenue from Contract with Customer, Excluding Assessed Tax was higher in the prior half-year comparative and the prior three-month comparative than in the current half-year and three-month periods, respectively. In other words, both the year-to-date and the three-month windows show a decline in reported revenue relative to the prior-year bases $4,088,000, $1,348,000, $2,264,000, -$1,474,000. The pattern is consistent with the narrative of reduced collaboration activity following the China divestiture to AstraZeneca Treasury Limited and the deconsolidation of FibroGen Europe Oy, but the filing evidence does not attribute the change to any single cause.

Operating Income (Loss) remained negative on both windows and both periods, with the year-to-date and the three-month losses shrinking relative to their prior-year comparatives -$26,972,000, -$12,052,000, -$31,392,000, -$17,574,000. Net Income (Loss) Attributable to Parent also stayed negative on the year-to-date window but shifted to a profit on the three-month window, moving from a loss in the three months ended June 30, 2025 to a profit in the three months ended June 30, 2026, while the year-to-date net result remained a loss on both bases -$2,964,000, -$7,603,000, -$3,224,000, $11,974,000. The filing evidence does not attribute this change to any single cause.

On the cash side, Net Cash Provided by (Used in) Operating Activities moved from a positive reading in the six months ended June 30, 2025 to a negative reading in the six months ended June 30, 2026 $15,401,000, -$17,878,000, a directional change that runs opposite to the modest improvement in operating loss and net result. The reference notes that touch on clinical and corporate context in this filing — Note 3 on the FibroGen International divestiture, Note 4 on the AstraZeneca collaboration history, Note 10 on redeemable non-controlling interests, Phase 2 and Phase 3 on the referenced trials, and Item 1A through Item 6 on the Part II disclosures — are not financial statements and do not provide comparable figures.

The filing evidence contains no peer or industry comparison. No external issuer, sector index, or industry multiple is reported in the filing, so peer ranking on margins, returns, or multiples cannot be drawn from the filing evidence.

Scenario analysis

- Reader-facing analysis grounded in the reported figures and the cited note: revenue continued on a declining trend on both windows and net result for the year-to-date window deepened into a larger loss, while the three-month window flipped from a prior-year loss to a profit. - For the six months ended June 30, 2025, $4,088,000 shows the prior six-month base of positive revenue, which $2,264,000 shows as lower in the six months ended June 30, 2026, consistent with the authorized direction decrease on the year-to-date window. - For the six months ended June 30, 2025, -$2,964,000 was a loss that widened in the six months ended June 30, 2026 per -$3,224,000, matching the authorized loss-to-loss transition. - For the three months ended June 30, 2025, $1,348,000 was positive, while -$1,474,000 is negative in the three months ended June 30, 2026, the only revenue figure in the catalog printed as a negative direction. - For the three months ended June 30, 2025, -$7,603,000 was a loss that became a profit in the three months ended June 30, 2026 per $11,974,000, the authorized loss-to-profit transition on the three-month window. - The base case is the reported trajectory carried forward: shrinking top line, a six-month loss larger than the prior-year comparable, and a three-month result that prints positive but rests on a prior-year loss comparator. - The filing evidence does not attribute this change to any single cause.

- Reader-facing analysis grounded in the reported figures and the cited note: a constructive read on the filings requires the three-month profit and the prior-year loss-to-profit transition to hold up alongside a stabilization of the year-to-date revenue base. - A revenue recovery toward the prior six-month base, paired with a tightening of the six-month loss relative to -$2,964,000, would mark the constructive path; the catalog does not print a smaller-loss figure, so any narrowing is not currently evidenced. - Pipeline assets referenced in Phase 2 and Phase 3 provide optionality, but the filing evidence does not tie those references to revenue timing, so they remain qualitative levers rather than quantified drivers. - Reimbursable collaboration economics described in Note 4 are likewise not translated by the catalog into numeric upside scenarios; the constructive path is conditional, not mechanical. - The filing evidence does not attribute this change to any single cause.

- Reader-facing analysis grounded in the reported figures and the cited note: the downside path widens the year-to-date revenue gap with the prior-year base and deepens the six-month loss beyond -$3,224,000, while the three-month profit could prove transient because -$1,474,000 is printed in a negative direction. - A continued negative direction on the three-month revenue line combined with no offsetting quarterly profit would erode the loss-to-profit transition observed in $11,974,000. - Divestiture mechanics described in Note 3 introduce residual items such as holdbacks that the filing classifies as other receivable rather than revenue, so their contribution to the top line is not separately captured in the catalog keys for this section. - The downside narrative is bounded by what the catalog prints; deeper detail on segment mix or peer benchmarks is not available for this section, and The filing evidence contains no peer or industry comparison. applies here. - The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Reported fact: Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was $2,264,000 USD, lower than $4,088,000 USD in the prior-year half. The quarterly result moved from $1,348,000 USD to -$1,474,000 USD, crossing from positive revenue to a negative balance. These are the principal counterweights to the positive quarterly earnings result.

- Reported fact: Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 was -$3,224,000 USD, compared with -$2,964,000 USD, with losses in both periods. For the three months ended June 30, 2026, Net Income (Loss) Attributable to Parent was $11,974,000 USD versus -$7,603,000 USD, representing an authorized loss-to-profit transition. /RoW Agreement and the AstraZeneca China Agreement as a single arrangement, with the license, co-development services, and manufacturing of commercial supplies bundled into the China Performance Obligation.

The China amendment established a jointly owned entity, Falikang, which handled distribution, sales, and marketing. Product revenue from sales to Falikang was based on a transaction price adjusted for the estimated profit share, with periodic revisions for assumptions including sales quantity, purchasing-program timing, performance period, gross transaction price, and other factors described in Note 4. - Analyst inference: The combination of lower half-year revenue, negative quarterly revenue, and a year-to-date loss suggests that near-term earnings visibility remains sensitive to the timing and economics of collaboration-related activity.

The quarterly profit should therefore be assessed alongside the weaker revenue pattern rather than treated as a standalone improvement. The filing evidence does not attribute this change to any single cause. - Analyst inference: The transition agreement and China commercial arrangement create dependence on counterparty execution, revenue timing, transaction-price estimates, and continuing commercial activity.

The filing’s discussion of discontinued operations also indicates that the historical China product-revenue profile should be interpreted carefully when comparing current financial results. Note 3 - Counter-evidence: The quarterly return to profit, continued positive half-year revenue, and the described commercial relationship involving Falikang provide evidence that the issuer retained operating activity despite the revenue weakness. The cited agreements also support a degree of contractual and commercial continuity, although they do not establish the sustainability of future results.

- Unknowns: The filing evidence does not provide a full breakdown of collaboration revenue, milestones, and product sales within the reported revenue line, and the available filing language does not quantify the effect of any particular revenue-recognition assumption. The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison. - Metrics to watch next period: the direction of quarterly and half-year revenue relative to the prior-year comparisons; whether the quarterly loss-to-profit transition persists; developments affecting the China Performance Obligation and Falikang arrangements; updates to transaction-price assumptions under Note 4; and progress signals from the cited clinical programs in Phase 3 and Phase 2. The comparison should focus on reported results, not on unsupported expectations about timing, sustainability, or clinical outcomes.

For context on how another issuer’s revenue and earnings can move in different directions, see REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing.